| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11654124 | AMNEAL | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives |
Jul, 2039
(15 years from now) | |
| US10792262 | AMNEAL | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives |
Jul, 2039
(15 years from now) | |
| US11491125 | AMNEAL | Baclofen formulations and methods of minimizing patient exposure to metabolite variations |
Sep, 2041
(17 years from now) | |
Lyvispah is owned by Amneal.
Lyvispah contains Baclofen.
Lyvispah has a total of 3 drug patents out of which 0 drug patents have expired.
Lyvispah was authorised for market use on 22 November, 2021.
Lyvispah is available in granules;oral dosage forms.
Lyvispah can be used as method for treating spasticity, treatment of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity.
The generics of Lyvispah are possible to be released after 29 September, 2041.
Drugs and Companies using BACLOFEN ingredient
Market Authorisation Date: 22 November, 2021
Treatment: Method for treating spasticity; Treatment of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity
Dosage: GRANULES;ORAL
LYVISPAH family patents
